Patient Recruitment Target Achieved in CLBP Pivotal Trial
Filed with ASX · · 3 pages · English
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallEarlier from Mesoblast
- Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
- Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products
- Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION
- Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
- Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy
Later from Mesoblast
- Mesoblast Draws US$50M from Five-Year Non-Dilutive Facility
- Ryoncil Q4 Net Revenue of US$36M and US$115M for Full Year
- Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
- Pivotal Phase 3 Trial in CLBP Achieves 300 Treated Patients
- Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast